Review of bimekizumab in the treatment of psoriasis
Open accessAbstract
Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these interleukins and the formation of psoriatic plaques. This review assesses the efficacy, safety, and implications of bimekizumab in the treatment of moderate-to-severe psoriasis. A review of literature was conducted using the PubMed repository in March 2022. Articles in English discussing the use of bimekizumab in the treatment of psoriasis were included. One phase II and four phase III trials were included. During clinical trials, bimekizumab was more efficacious, when compared to placebo, ustekinumab, adalimumab, and secukinumab in the treatment of moderate to severe psoriasis. Bimekizumab is a promising, efficacious, and relatively tolerable emerging systemic treatment for moderate-to-severe plaque psoriasis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The IL-23/Th17 axis is a central driver of psoriasis.
“The identification of the IL-23/Th17 axis as a central driver of psoriasis has led to the development of biologic therapies that selectively interrupt cytokine networks.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [30]
The 'Basis in pathology' section (page unavailable) says Th17 cells produce IL-17 and that IL-17 is crucial to psoriatic plaque formation. The 'IL-17 inhibitors' section says IL-17 is a major cytokine in psoriasis and that biologics selectively target it. The review lists IL-23 inhibitors, but does not explain or identify the IL-23/Th17 axis as a central driver. (LLM, conf=0.82)
Experimental — accuracy not yet measuredSelective IL-23 inhibitors show high efficacy with durable responses in psoriasis, likely by disrupting the maintenance of disease-driving Th17 cells.
“selective IL-23 inhibitors have also shown high efficacy with durable responses, likely by disrupting the maintenance of disease-driving Th17 cells [29,30,31,32].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [30]
The Advantages/disadvantages section describes IL-23 inhibitors as efficacious for psoriasis and reports favorable PASI90 results for risankizumab and guselkumab. It does not establish durable responses or say that IL-23 inhibition disrupts the maintenance of disease-driving Th17 cells; its discussion of Th17 cells in Basis in pathology does not make that connection. Page numbers were not available in our copy. (LLM, conf=0.82)
Experimental — accuracy not yet measuredTherapies targeting IL-17, including monoclonal antibodies against IL-17A or its receptor, produce rapid and efficient clinical responses in psoriasis by suppressing keratinocyte activation and neutrophil recruitment, which are key downstream effects of Th17 immunity.
“Therapies targeting IL-17 (monoclonal antibodies against IL-17A or its receptor) have shown rapid and efficient clinical responses by directly suppressing keratinocyte activation and neutrophil recruitment, which are key downstream effects of Th17 immunity.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [30]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredPsoriasis histopathological findings reflect activation of the IL-23/Th17 axis.
“These reflect activation of the IL-23/Th17 axis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [30]
The “Basis in pathology” section (page unavailable) links Th17 activation and IL-17 activity to psoriatic plaques and epidermal hyperplasia. It does not explicitly link the histopathological findings to activation of the full IL-23/Th17 axis; IL-23 appears in the supplied passages only in treatment classes and references. (LLM, conf=0.82)
Experimental — accuracy not yet measuredIn psoriasis, histopathological findings include acanthosis, parakeratosis, neutrophilic microabscesses, and prominent dermal vascular proliferation.
“In psoriasis, histopathological findings include acanthosis, parakeratosis, neutrophilic microabscesses, and prominent dermal vascular proliferation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [30]
The “Basis in pathology” section (page unavailable) describes keratinocyte proliferation and epidermal hyperplasia, which support the acanthosis component. It does not describe parakeratosis, neutrophilic microabscesses, or prominent dermal vascular proliferation. (LLM, conf=0.83)
Experimental — accuracy not yet measured
IL-23 is an upstream regulator of pathogenic T-cell populations in psoriasis.
“Furthermore, increasing evidence supports IL-23 as an upstream regulator of pathogenic T-cell populations; thus, selective IL-23 inhibitors have also shown high efficacy with durable responses, likely by disrupting the maintenance of disease-driving Th17 cells [29,30,31,32].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [30]
The ‘Basis in pathology’ section describes activation of Th17 cells by myeloid dendritic cells and identifies IL-17 as a contributor to psoriasis, but it does not say IL-23 regulates those cells. Searches for IL-23 as an upstream regulator or maintainer of Th17 cells found only mentions of IL-23 inhibitors and a reference title, not a passage making the claimed connection. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,364 · see citing works
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C.-C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 601 · see citing works
Management of psoriasis as a systemic disease: what is the evidence?
Korman, N. J. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18245 · Cited by 546 · see citing works
Raharja, A., Mahil, S. K., & Barker, J. N. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0257 · Cited by 443 · see citing works
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B. E., Langley, R. G. B., Paul, C. F., Cuyper, D. D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 427 · see citing works
Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G. B., Armstrong, A. W., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00125-2 · Cited by 317 · see citing works
Gordon, K. B., Foley, P. A., Krueger, J. G., Pinter, A., Reich, K., Vender, R. B., Vanvoorden, V., Madden, C., White, K., Cioffi, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00126-4 · Cited by 298 · see citing works
Bimekizumab versus Adalimumab in Plaque Psoriasis
Warren, R. B., Blauvelt, A., Bagel, J., Papp, K. A., Yamauchi, P. S., Armstrong, A. W., Langley, R. G. B., Vanvoorden, V., Cuyper, D. D., Cioffi, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102388 · Cited by 253 · see citing works
Psoriasis and Treatment: Past, Present and Future Aspects
Reid, C., & Griffiths, C. E. M. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3386 · Cited by 221 · see citing works
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192 · see citing works
Self-citationBimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Adams, R., Maroof, A., BAKER, T. S., Lawson, A. D. G., Oliver, R., Paveley, R. A., Rapecki, S., Shaw, S., Vajjah, P., West, S. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01894 · Cited by 190 · see citing works
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.037 · Cited by 188 · see citing works
Bai, F., Li, G. G., Liu, Q., Niu, X., Li, R., & Ma, H. (2019) · Journal of Immunology Research · doi:10.1155/2019/2546161 · Cited by 176 · see citing works
Vanessa Ocampo, D., & Gladman, D. D. (2019) · F1000Research · doi:10.12688/f1000research.19144.1 · Cited by 174 · see citing works
Return-to-work, disabilities and occupational health in the age of COVID-19
Godeau, D., Petit, A., Richard, I., Roquelaure, Y., & Descatha, A. (2021) · Scandinavian Journal of Work, Environment & Health · doi:10.5271/sjweh.3960 · Cited by 153 · see citing works
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, É., Chaimani, A., García-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Cleach, L. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub5 · Cited by 148 · see citing works
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
Huppler, A. R., Bishu, S., & Gaffen, S. L. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3893 · Cited by 142 · see citing works
Glatt, S., Helmer, E., Haier, B., Strimenopoulou, F., Price, G., Vajjah, P., Harari, O., Lambert, J., & Shaw, S. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13185 · Cited by 142 · see citing works
Bellinato, F., Gisondi, P., & Girolomoni, G. (2021) · Biologics · doi:10.2147/btt.s290309 · Cited by 53 · see citing works
Bimekizumab for the Treatment of Psoriasis
Freitas, E., Blauvelt, A., & Torres, T. R. (2021) · Drugs · doi:10.1007/s40265-021-01612-z · Cited by 47 · see citing works
Bakar, R. S., Jaapar, S. Z. S., Azmi, A. F., & Aun, Y. C. (2021) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2021.02.008 · Cited by 45 · see citing works
Reis, J., Vender, R. B., & Torres, T. R. (2019) · BioDrugs · doi:10.1007/s40259-019-00361-6 · Cited by 42 · see citing works
Monks, G., Rivera‐Oyola, R., & Lebwohl, M. (2021) · PubMed · Cited by 14 · see citing works
Bimekizumab: the new drug in the biologics armamentarium for psoriasis
Freitas, E., & Torres, T. (2021) · Drugs in Context · doi:10.7573/dic.2021-4-1 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies
Davis, M. S., Spencer, R. K., Johnson, C. E., Elhage, K. G., Jin, J. Q., Hakimi, M., Bhutani, T., & Liao, W. J. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01074-z · Cited by 15 · see citing works
Deciphering the Receptor-Mediated Signaling Pathways of Interleukin-19 and Interleukin-20
Shaji, V., Dagamajalu, S., Sanjeev, D., George, M., Kanekar, S., Prasad, G., Prasad, T. S. K., Raju, R., & Balaya, R. D. A. (2024) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2024.0009 · Cited by 7 · see citing works
Wang, Z., Jiang, X., Jiang, C., Tao, X., & Ye, J. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101512 · Cited by 6 · see citing works
Lin, Z., Yu, X., Yang, M., Xu, J., & Zhong, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1714173 · Cited by 5 · see citing works
Bimekizumab for The Treatment of Psoriasis
Thapar, M., Patel, M., & Gordon, K. B. (2024) · Immunotherapy · doi:10.2217/imt-2023-0240 · Cited by 2 · see citing works
AlShaikh, S. A., Almarhoon, Z., Momattin, H., Aleid, M., Almousa, Z., Alqaisum, A., Mobarki, F., Almakki, S., Alturfi, H., & Almajed, K. (2025) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s544166 · Cited by 2 · see citing works
Monoklonale Antikörper für entzündliche, autoimmune und onkologische Hauterkrankungen
Kinberger, M., Dobos, G., & Solimani, F. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05413-9 · Cited by 2 · see citing works
Paradoxical dyshidrosis following bimekizumab treatment for severe recalcitrant psoriasis
Thiagarajan, A. B., Horton, L. A., & Lee, B. A. (2025) · JAAD Case Reports · doi:10.1016/j.jdcr.2025.10.062 · Cited by 2 · see citing works
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1 · see citing works
Psoriasis: eine Systemerkrankung mit multiplen Behandlungsoptionen
Seidel, P., & Magnolo, N. (2023) · ästhetische dermatologie & kosmetologie · doi:10.1007/s12634-023-2354-x
Tian, T., Tian, T., Hong, T., He, Y., Wang, X., Qian, L., Deng, S., Zhou, R., Jiang, M., Fan, J., et al. (2026) · Journal of Global Health · doi:10.7189/jogh.16.04179
- Authors
- Koppu, S., Singh, R., Kaur, K., & Feldman, S. R.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Singh, Rohan
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2022-09-12
- Volume
- 18
- Issue
- 6
- Pages
- 2119767-2119767
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC9746354
- OpenAlex
- W4295886153
- Cited by
- 11
- References
- 24
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 2
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- no funding
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- bimekizumab, psoriasis, IL-19, IL-22, IL-36, systemic therapy, drug efficacy, drug safety, ustekinumab, adalimumab, secukinumab
- MeSH terms
- Ustekinumab, Antibodies, Monoclonal, Humans, Psoriasis, Severity of Illness Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
